DSIP
Delta sleep-inducing peptide — nine amino acids
A nine-amino-acid peptide isolated for its effects on sleep in animals. Decades of small human studies produced inconsistent results, and nothing was ever approved.
- Category
- Cognitive
- Half-life
- Very short — the peptide is cleared within minutes
- Cycle length
- Not established — no validated protocol exists
- Level
- intermediate
Overview
Delta sleep-inducing peptide was isolated in the 1970s from rabbit brain perfusate because it appeared to induce the slow-wave sleep pattern seen on EEG. For a period it looked like the beginning of a pharmacology of sleep architecture rather than sedation. Half a century later, DSIP is sold as a research peptide for sleep, and the human evidence remains a collection of small, mostly uncontrolled studies with inconsistent findings. It is a useful example of how a compelling name outlives a weak evidence base.
How it works
DSIP is a nine-amino-acid peptide found in the brain and periphery. Reported effects include modulation of slow-wave sleep, influence on circadian and stress-related hormone release, and interaction with pain and opioid systems in animal models. No receptor has been definitively identified and no coherent mechanism explains both the animal and the human findings, which is a large part of why the literature never converged.
Reported benefits
- Increased slow-wave EEG activity in some early animal and human studies
- Reported subjective improvements in sleep quality in small studies
- Effects on stress-hormone release in some experimental settings
- One of the longest-studied sleep-related peptides
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
There is no established dose. Studies since the 1970s used intravenous or intranasal administration in small numbers of subjects. Community figures of a few hundred micrograms before sleep are not derived from controlled dose-finding trials.
Because the peptide's measured effect on sleep architecture has been inconsistent across studies, there is no basis for a standardised human protocol, and reported doses vary by more than an order of magnitude between sources.
Community-reported: 100–300 mcg before sleep, one to five nights weekly, sometimes only around travel or shift changes.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
The DSIP literature is old and thin. Studies in the 1970s and 1980s reported changes in sleep EEG and in hormone rhythms, but sample sizes were small, controls were often absent, and results were not consistently reproduced. Later reviews have generally concluded that the evidence for a reliable effect on human sleep is weak and that the peptide's pharmacology remains poorly defined. For a reader, DSIP is best understood as a historical curiosity that survives commercially. If the goal is better sleep, the interventions with real evidence are behavioural — and the peptides in this library that people take for sleep are not among them.
Preclinical & non-clinical data
Discovered through rabbit sleep studies decades ago. The mechanism was never clearly established, and modern human data is essentially absent — the compound remains more of a historical curiosity than a characterised drug.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
Sleep is the whole conversation. Users report faster sleep onset and deeper sleep, sometimes with vivid dreams, and travel-focused users report it as a jet-lag tool. The counter-reports matter just as much: next-day grogginess or heaviness in some accounts, a complete absence of effect in others, and a strong suspicion of placebo given how variable the responses are.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Headache reported anecdotally
- Daytime grogginess or vivid dreams reported by users
- Injection-site reactions
- No systematic human safety data
Safety notes
No modern human safety data exists. As with all unregulated peptides, identity and purity of supplied material are unverified, and effects on sleep architecture cannot be assessed without EEG monitoring. Do not combine with sedatives, sleep medication or alcohol without clinical advice.
Stacking
Sometimes combined with other sleep or recovery peptides, a practice with no supporting evidence and no way to detect an interaction.
Related compounds
Semax
ACTH(4-10) analogue
Cognitive
A Russian nootropic peptide with genuine human data behind it.
Cerebrolysin
Porcine brain-derived peptide preparation
Cognitive
A peptide mixture from porcine brain, used clinically in some countries and unapproved in others.
Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide — angiotensin IV analogue
Cognitive
A cognitive-enhancement candidate with striking animal data and no human testing.